Repurposing FDA-approved drugs as inhibitors of therapy-induced invadopodia activity in glioblastoma cells

Glioblastoma (GBM) is the most prevalent primary central nervous system tumour in adults. The lethality of GBM lies in its highly invasive, infiltrative, and neurologically destructive nature resulting in treatment failure, tumour recurrence and death. Even with current standard of care treatment wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Dylan, Whitehead, Clarissa A., Dinevska, Marija, Widodo, Samuel S., Furst, Liam M., Morokoff, Andrew P., Kaye, Andrew H., Drummond, Katharine J., Mantamadiotis, Theo, Stylli, Stanley S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164021/
https://www.ncbi.nlm.nih.gov/pubmed/36302993
http://dx.doi.org/10.1007/s11010-022-04584-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164021/
https://www.ncbi.nlm.nih.gov/pubmed/36302993
http://dx.doi.org/10.1007/s11010-022-04584-0

Ejemplares similares